CardioVascular and Interventional Radiology

, Volume 34, Issue 2, pp 391–395 | Cite as

Irreversible Electroporation in a Swine Lung Model

  • Damian E. Dupuy
  • Bassam Aswad
  • Thomas Ng
Laboratory Investigation



This study was designed to evaluate the safety and tissue effects of IRE in a swine lung model.


This study was approved by the institutional animal care committee. Nine anesthetized domestic swine underwent 15 percutaneous irreversible electroporation (IRE) lesion creations (6 with bipolar and 3 with 3–4 monopolar electrodes) under fluoroscopic guidance and with pancuronium neuromuscular blockade and EKG gating. IRE electrodes were placed into the central and middle third of the right mid and lower lobes in all animals. Postprocedure PA and lateral chest radiographs were obtained to evaluate for pneumothorax. Three animals were sacrificed at 2 weeks and six at 4 weeks. Animals underwent high-resolution CT scanning and PA and lateral radiographs 1 h before sacrifice. The treated lungs were removed en bloc, perfused with formalin, and sectioned. Gross pathologic and microscopic changes after standard hematoxylin and eosin staining were analyzed within the areas of IRE lesion creation.


No significant adverse events were identified. CT showed focal areas of spiculated high density ranging in greatest diameter from 1.1–2.2 cm. On gross inspection of the sectioned lung, focal areas of tan discoloration and increased density were palpated in the areas of IRE. Histological analysis revealed focal areas of diffuse alveolar damage with fibrosis and inflammatory infiltration that respected the boundaries of the interlobular septae. No pathological difference could be discerned between the 2- and 4-week time points. The bronchioles and blood vessels within the areas of IRE were intact and did not show signs of tissue injury.


IRE creates focal areas of diffuse alveolar damage without creating damage to the bronchioles or blood vessels. Short-term safety in a swine model appears to be satisfactory.


Ablation Zone Diffuse Alveolar Damage High Direct Current Voltage Irreversible Electroporation Monopolar Electrode 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest

Damian E. Dupuy, M.D. received grant support from Angiodynamics (Latham, NY) for this study and has received speaking honoraria from Angiodynamics.


  1. 1.
    Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST (2010) Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 255:426–433CrossRefPubMedGoogle Scholar
  2. 2.
    Esser AT, Smith KC, Gowrishankar TR, Weaver JC (2007) Towards solid tumor treatment by irreversible electroporation: intrinsic redistribution of fields and currents in tissue. Technol Cancer Res Treat 6:261–274PubMedGoogle Scholar
  3. 3.
    Davalos RV, Mir IL, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng 33:223–231CrossRefPubMedGoogle Scholar
  4. 4.
    Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadossi R (2007) Design of an irreversible electroporation system for clinical use. Technol Cancer Res Treat 6:313–320PubMedGoogle Scholar
  5. 5.
    Edd JF, Davalos RV (2007) Mathematical modeling of irreversible electroporation for treatment planning. Technol Cancer Res Treat 6:275–286PubMedGoogle Scholar
  6. 6.
    Rabussay DP, Nanada GS, Goldfarb PM (2002) Enhancing the effectiveness of drug based cancer therapy by electroporation (electropermeabilization). Technol Cancer Res Treat 1:71–82PubMedGoogle Scholar
  7. 7.
    Goldberg SN, Dupuy DE (2001) Image-guided radiofrequency tumor ablation: challenges and opportunities part 1. J Vasc Interv Radiol 12:1021–1032CrossRefGoogle Scholar
  8. 8.
    McTaggart RA, Dupuy DE (2007) Thermal ablation of lung tumors. Tech Vasc Interv Radiol 10:102–113CrossRefPubMedGoogle Scholar
  9. 9.
    Miller L, Leor J, Rubinsky B (2005) Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat 4:699–705PubMedGoogle Scholar
  10. 10.
    Al-Sakere B, Andre F, Bernat C, Connault E, Opolon P et al (2007) Tumor ablation with irreversible electroporation. PLoS ONE 2:e1135CrossRefPubMedGoogle Scholar
  11. 11.
    Onik G, Mikus P, Rubinsky B (2007) Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 4:295–300Google Scholar
  12. 12.
    Rubinsky B, Onik G, Mikus P (2007) Irreversible electroporation: a new modality clinical implications. Technol Cancer Res Treat 6:37–48PubMedGoogle Scholar
  13. 13.
    Allegretti JP, Panje WR (2001) Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 111:52–56CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010

Authors and Affiliations

  1. 1.Rhode Island HospitalThe Warren Alpert Medical School of Brown UniversityProvidenceUSA
  2. 2.Department of Pathology, Rhode Island HospitalThe Warren Alpert Medical School of Brown UniversityProvidenceUSA
  3. 3.Department of Surgery, Rhode Island HospitalThe Warren Alpert Medical School of Brown UniversityProvidenceUSA

Personalised recommendations